Gilead Valuation Only Minimally Effected By Drug Trial Stoppage
September 22, 2016 at 15:38 PM EDT
Following Gilead Sciences, Inc.'s (NASDAQ: GILD) announcement that it's stalling the Phase 2/3 study of its ulcerative ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.